GlassScriptPhysician profile
Andrew Thomas Melcher
NPI 1205455631
$2,465.31
in general payments reported to CMS, 2019-2025
23 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $291 · 2023: $830 · 2024: $532 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.29 | 2021-2025 | |
| Ucb, INC. | $437.30 | 2023-2025 | Briviact, Fintepla |
| Teva Pharmaceuticals USA, INC. | $265.12 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurelis, INC. | $196.50 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $112.73 | 2022-2024 | |
| Argenx US, INC. | $105.06 | 2025 | Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $100.31 | 2021 | |
| Emd Serono, INC. | $74.68 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $68.15 | 2021-2025 | Ultomiris |
| Pfizer INC. | $58.18 | 2025 | |
| Csl Behring | $56.92 | 2023-2024 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $47.88 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $37.82 | 2022 | |
| Amgen INC. | $34.26 | 2024 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $33.88 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $33.26 | 2023-2024 | Spinraza, Vumerity |
| Tanabe Pharma America, INC. | $22.56 | 2025 | Radicava |
| Lundbeck LLC | $22.24 | 2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $21.88 | 2025 | Inbrija, Ampyra, Xeomin |
| Genentech USA, INC. | $18.70 | 2024 | Ocrevus Zunovo |
| Eisai INC. | $18.28 | 2025 | |
| Vanda Pharmaceuticals INC. | $16.70 | 2025 | Ponvory |
| Janssen Biotech, INC. | $16.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Melcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.